news
Pfizer and BioNTech may supply EU with 200 million doses of COVID-19 vaccine
The companies and European Commission will soon enter contract negotiations for the supply of their investigational COVID-19 vaccine candidate BNT162b2.
List view / Grid view
BioNTech
Filter the results
news
Pfizer and BioNTech COVID-19 vaccine candidate enters Phase II/III trials
The BNT162b2 mRNA-based vaccine produced by Pfizer and BioNTech will enter Phase have II/III clinical trials to test its safety and efficacy against COVID-19.
news
Pfizer and BioNTech to supply up to 600 million doses of COVID-19 vaccine to US
An agreement between the US government and Pfizer and BioNTech will have the companies produce an initial 100 million doses of their COVID-19 vaccine candidate, with the potential for 500 million more.
news
UK government secures early access to 90 million doses of COVID-19 vaccines
The government has entered partnerships with Pfizer and Valneva to secure doses of several promising COVID-19 vaccines and secured COVID-19 neutralising antibody treatments from AstraZeneca.
news
First patient dosed with Pfizer’s potential COVID-19 vaccine in US
Pfizer and BioNTech have initiated Phase I/II trials in the US to determine the safety and optimal dose of four mRNA COVID-19 vaccine candidates.
news
Germany to begin first clinical trial of COVID-19 vaccine candidate
A Phase I/II clinical trial for BioNTech's BNT162 vaccine programme to prevent COVID-19 infection has been granted approval in Germany.
article
COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
article
Potential COVID-19 therapeutics currently in development
As the world rushes to identify the best coronavirus treatments and vaccines, John Cahill rounds up the latest developments in potential COVID-19 therapies.